Denosumab效果好吗？

Is it effective? In 2015, The Lancet published the preliminary results of the randomized double-blind placebo-controlled phase III study (ABCSG-18) of the Austrian Breast and Colorectal Cancer Research Group (ABCSG), which showed that using denosumab as an adjuvant drug for AI therapy can significantly reduce clinical SREs. On February 19, 2019, Lancet oncology published the ABCSG-18 disease-free survival results online. 

In this multicenter, prospective, double-blind, placebo-controlled phase 3 trial, conducted at 58 sites in Austria and Sweden, from December 18, 2006, to July 22, 2013, a total of 3425 patients with early-stage HR-positive postmenopausal, non-metastatic breast cancer who had completed their initial adjuvant treatment pathway (surgery, radiotherapy, chemotherapy, or combination therapy) and were receiving adjuvant AI therapy were enrolled. Patients were allocated on a 1:1 basis, with 1,711 patients assigned to the Denosumab group and 1,709 patients assigned to the placebo group, receiving subcutaneous injections of Denosumab (60 mg) or matching placebo every 6 months during aromatase inhibitor treatment. The study concluded that Denosumab is a safe and effective adjuvant treatment for postmenopausal patients with hormone receptor-positive early breast cancer receiving aromatase inhibitor therapy.

Physicians should evaluate the need to continue treatment with Denosumab in patients who develop serious infections during use. Osteonecrosis of the jaw often occurs with tooth extraction and local infection that delays healing. A routine oral examination should be performed before starting Denosumab treatment, and good oral hygiene should be maintained after treatment is started. If a patient develops osteonecrosis of the jaw, treatment for the osteonecrosis of the jaw may actually aggravate the condition. In this case, discontinuation of Denosumab should be considered.